The global market for Active Pharmaceutical Ingredients (API) CDMO was estimated to be worth US$ 53870 million in 2023 and is forecast to a readjusted size of US$ 93530 million by 2030 with a CAGR of 8.2% during the forecast period 2024-2030

Active Pharmaceutical Ingredients (API) CDMO - Market

Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) provides services related to the development, manufacturing, and supply of active pharmaceutical ingredients used in the formulation of pharmaceutical products. API CDMOs play a crucial role in the pharmaceutical industry by assisting pharmaceutical companies in bringing their drug products to market efficiently and cost-effectively.

The global market for Active Pharmaceutical Ingredients (API) Contract Development and Manufacturing Organization (CDMO) services has experienced significant growth in recent years. API CDMOs play a critical role in the pharmaceutical industry by offering specialized expertise and capabilities in API development and manufacturing. The expanding pharmaceutical sector, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical treatments, has fueled the demand for API CDMO services. Pharmaceutical companies have increasingly turned to API CDMOs for cost-effective and time-efficient solutions, enabling them to focus on core competencies, research, and commercialization. The United States and Canada are major consumers of API CDMO services due to a large number of pharmaceutical companies and a robust drug development landscape. European countries, including the United Kingdom, Germany, and Switzerland, have a well-established pharmaceutical industry, contributing to significant demand for API CDMO services. Countries like India, China, and South Korea have emerged as major players in the API CDMO market, offering cost-competitive services and a skilled workforce. The global market for API CDMO services is expected to continue its growth trajectory in the coming years. As pharmaceutical companies seek to streamline their drug development processes, reduce costs, and access specialized expertise, API CDMOs will play a pivotal role in supporting the industry. Moreover, as the pharmaceutical landscape continues to evolve with the introduction of innovative therapies and biologics, API CDMOs will likely invest in advanced technologies and expand their service offerings to cater to the evolving needs of pharmaceutical companies.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Active Pharmaceutical Ingredients (API) CDMO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Active Pharmaceutical Ingredients (API) CDMO by region & country, by Type, and by Application.

The Active Pharmaceutical Ingredients (API) CDMO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Active Pharmaceutical Ingredients (API) CDMO.

Market Segmentation

Scope of Active Pharmaceutical Ingredients (API) CDMO - Market Report

Report Metric	Details
Report Name	Active Pharmaceutical Ingredients (API) CDMO - Market
Forecasted market size in 2030	US$ 93530 million
CAGR	8.2%
Forecasted years	2024 - 2030
Segment by Type:	Macromolecular API Small Molecule API
Segment by Application	Clinical Commercial Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma, Lonza, Siegfried, Catalent, Boehringer Ingelheim, Piramal Group, AbbVie, SGS Quay Pharmaceuticals, Aenova Group, Curia, Sterling Pharma Solutions, Eurofins CDMO
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Active Pharmaceutical Ingredients (API) CDMO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Active Pharmaceutical Ingredients (API) CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Active Pharmaceutical Ingredients (API) CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Active Pharmaceutical Ingredients (API) CDMO - Market size in 2030?

Ans: The Active Pharmaceutical Ingredients (API) CDMO - Market size in 2030 will be US$ 93530 million.

Who are the main players in the Active Pharmaceutical Ingredients (API) CDMO - Market report?

Ans: The main players in the Active Pharmaceutical Ingredients (API) CDMO - Market are Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma, Lonza, Siegfried, Catalent, Boehringer Ingelheim, Piramal Group, AbbVie, SGS Quay Pharmaceuticals, Aenova Group, Curia, Sterling Pharma Solutions, Eurofins CDMO

What are the Application segmentation covered in the Active Pharmaceutical Ingredients (API) CDMO - Market report?

Ans: The Applications covered in the Active Pharmaceutical Ingredients (API) CDMO - Market report are Clinical, Commercial, Others

What are the Type segmentation covered in the Active Pharmaceutical Ingredients (API) CDMO - Market report?

Ans: The Types covered in the Active Pharmaceutical Ingredients (API) CDMO - Market report are Macromolecular API, Small Molecule API

1 Market Overview

1.1 Active Pharmaceutical Ingredients (API) CDMO Product Introduction

1.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size Forecast

1.3 Active Pharmaceutical Ingredients (API) CDMO Market Trends & Drivers

1.3.1 Active Pharmaceutical Ingredients (API) CDMO Industry Trends

1.3.2 Active Pharmaceutical Ingredients (API) CDMO Market Drivers & Opportunity

1.3.3 Active Pharmaceutical Ingredients (API) CDMO Market Challenges

1.3.4 Active Pharmaceutical Ingredients (API) CDMO Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Active Pharmaceutical Ingredients (API) CDMO Players Revenue Ranking (2023)

2.2 Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Company (2019-2024)

2.3 Key Companies Active Pharmaceutical Ingredients (API) CDMO Manufacturing Base Distribution and Headquarters

2.4 Key Companies Active Pharmaceutical Ingredients (API) CDMO Product Offered

2.5 Key Companies Time to Begin Mass Production of Active Pharmaceutical Ingredients (API) CDMO

2.6 Active Pharmaceutical Ingredients (API) CDMO Market Competitive Analysis

2.6.1 Active Pharmaceutical Ingredients (API) CDMO Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Macromolecular API

3.1.2 Small Molecule API

3.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type

3.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value, by Type (2019-2030)

3.2.3 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Clinical

4.1.2 Commercial

4.1.3 Others

4.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application

4.2.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value, by Application (2019-2030)

4.2.3 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region

5.1.1 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (2019-2024)

5.1.3 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (2025-2030)

5.1.4 Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

5.2.2 North America Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

5.3.2 Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

5.4.2 Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

5.5.2 South America Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

5.6.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Active Pharmaceutical Ingredients (API) CDMO Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Active Pharmaceutical Ingredients (API) CDMO Sales Value

6.3 United States

6.3.1 United States Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.3.2 United States Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.4.2 Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.5.2 China Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.5.3 China Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.6.2 Japan Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.7.2 South Korea Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.8.2 Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019-2030

6.9.2 India Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

6.9.3 India Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Recipharm

7.1.1 Recipharm Profile

7.1.2 Recipharm Main Business

7.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.1.4 Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.1.5 Recipharm Recent Developments

7.2 Cambrex Corporation

7.2.1 Cambrex Corporation Profile

7.2.2 Cambrex Corporation Main Business

7.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.2.4 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.2.5 Cambrex Corporation Recent Developments

7.3 Patheon (Thermo Fisher Scientific)

7.3.1 Patheon (Thermo Fisher Scientific) Profile

7.3.2 Patheon (Thermo Fisher Scientific) Main Business

7.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.3.4 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.3.5 CordenPharma Recent Developments

7.4 CordenPharma

7.4.1 CordenPharma Profile

7.4.2 CordenPharma Main Business

7.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.4.4 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.4.5 CordenPharma Recent Developments

7.5 Lonza

7.5.1 Lonza Profile

7.5.2 Lonza Main Business

7.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.5.4 Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.5.5 Lonza Recent Developments

7.6 Siegfried

7.6.1 Siegfried Profile

7.6.2 Siegfried Main Business

7.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.6.4 Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.6.5 Siegfried Recent Developments

7.7 Catalent

7.7.1 Catalent Profile

7.7.2 Catalent Main Business

7.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.7.4 Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.7.5 Catalent Recent Developments

7.8 Boehringer Ingelheim

7.8.1 Boehringer Ingelheim Profile

7.8.2 Boehringer Ingelheim Main Business

7.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.8.4 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.8.5 Boehringer Ingelheim Recent Developments

7.9 Piramal Group

7.9.1 Piramal Group Profile

7.9.2 Piramal Group Main Business

7.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.9.4 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.9.5 Piramal Group Recent Developments

7.10 AbbVie

7.10.1 AbbVie Profile

7.10.2 AbbVie Main Business

7.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.10.4 AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.10.5 AbbVie Recent Developments

7.11 SGS Quay Pharmaceuticals

7.11.1 SGS Quay Pharmaceuticals Profile

7.11.2 SGS Quay Pharmaceuticals Main Business

7.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.11.4 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.11.5 SGS Quay Pharmaceuticals Recent Developments

7.12 Aenova Group

7.12.1 Aenova Group Profile

7.12.2 Aenova Group Main Business

7.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.12.4 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.12.5 Aenova Group Recent Developments

7.13 Curia

7.13.1 Curia Profile

7.13.2 Curia Main Business

7.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.13.4 Curia Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.13.5 Curia Recent Developments

7.14 Sterling Pharma Solutions

7.14.1 Sterling Pharma Solutions Profile

7.14.2 Sterling Pharma Solutions Main Business

7.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.14.4 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.14.5 Sterling Pharma Solutions Recent Developments

7.15 Eurofins CDMO

7.15.1 Eurofins CDMO Profile

7.15.2 Eurofins CDMO Main Business

7.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

7.15.4 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue (US$ Million) & (2019-2024)

7.15.5 Eurofins CDMO Recent Developments

8 Industry Chain Analysis

8.1 Active Pharmaceutical Ingredients (API) CDMO Industrial Chain

8.2 Active Pharmaceutical Ingredients (API) CDMO Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Active Pharmaceutical Ingredients (API) CDMO Sales Model

8.5.2 Sales Channel

8.5.3 Active Pharmaceutical Ingredients (API) CDMO Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Recipharm

Cambrex Corporation

Patheon (Thermo Fisher Scientific)

SGS Quay Pharmaceuticals

Aenova Group

Curia

Sterling Pharma Solutions

Eurofins CDMO

List of Tables

Table 1. Active Pharmaceutical Ingredients (API) CDMO Market Trends

Table 2. Active Pharmaceutical Ingredients (API) CDMO Market Drivers & Opportunity

Table 3. Active Pharmaceutical Ingredients (API) CDMO Market Challenges

Table 4. Active Pharmaceutical Ingredients (API) CDMO Market Restraints

Table 5. Global Active Pharmaceutical Ingredients (API) CDMO Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Active Pharmaceutical Ingredients (API) CDMO Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Active Pharmaceutical Ingredients (API) CDMO Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Active Pharmaceutical Ingredients (API) CDMO Product Type

Table 9. Key Companies Time to Begin Mass Production of Active Pharmaceutical Ingredients (API) CDMO

Table 10. Global Active Pharmaceutical Ingredients (API) CDMO Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Active Pharmaceutical Ingredients (API) CDMO as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Active Pharmaceutical Ingredients (API) CDMO Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (2019-2024) & (%)

Table 27. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Active Pharmaceutical Ingredients (API) CDMO Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2025-2030) & (US$ Million)

Table 31. Recipharm Basic Information List

Table 32. Recipharm Description and Business Overview

Table 33. Recipharm Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 34. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Recipharm (2019-2024)

Table 35. Recipharm Recent Developments

Table 36. Cambrex Corporation Basic Information List

Table 37. Cambrex Corporation Description and Business Overview

Table 38. Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 39. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Cambrex Corporation (2019-2024)

Table 40. Cambrex Corporation Recent Developments

Table 41. Patheon (Thermo Fisher Scientific) Basic Information List

Table 42. Patheon (Thermo Fisher Scientific) Description and Business Overview

Table 43. Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 44. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Patheon (Thermo Fisher Scientific) (2019-2024)

Table 45. Patheon (Thermo Fisher Scientific) Recent Developments

Table 46. CordenPharma Basic Information List

Table 47. CordenPharma Description and Business Overview

Table 48. CordenPharma Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 49. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of CordenPharma (2019-2024)

Table 50. CordenPharma Recent Developments

Table 51. Lonza Basic Information List

Table 52. Lonza Description and Business Overview

Table 53. Lonza Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 54. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Lonza (2019-2024)

Table 55. Lonza Recent Developments

Table 56. Siegfried Basic Information List

Table 57. Siegfried Description and Business Overview

Table 58. Siegfried Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 59. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Siegfried (2019-2024)

Table 60. Siegfried Recent Developments

Table 61. Catalent Basic Information List

Table 62. Catalent Description and Business Overview

Table 63. Catalent Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 64. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Catalent (2019-2024)

Table 65. Catalent Recent Developments

Table 66. Boehringer Ingelheim Basic Information List

Table 67. Boehringer Ingelheim Description and Business Overview

Table 68. Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 69. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Boehringer Ingelheim (2019-2024)

Table 70. Boehringer Ingelheim Recent Developments

Table 71. Piramal Group Basic Information List

Table 72. Piramal Group Description and Business Overview

Table 73. Piramal Group Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 74. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Piramal Group (2019-2024)

Table 75. Piramal Group Recent Developments

Table 76. AbbVie Basic Information List

Table 77. AbbVie Description and Business Overview

Table 78. AbbVie Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 79. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of AbbVie (2019-2024)

Table 80. AbbVie Recent Developments

Table 81. SGS Quay Pharmaceuticals Basic Information List

Table 82. SGS Quay Pharmaceuticals Description and Business Overview

Table 83. SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 84. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of SGS Quay Pharmaceuticals (2019-2024)

Table 85. SGS Quay Pharmaceuticals Recent Developments

Table 86. Aenova Group Basic Information List

Table 87. Aenova Group Description and Business Overview

Table 88. Aenova Group Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 89. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Aenova Group (2019-2024)

Table 90. Aenova Group Recent Developments

Table 91. Curia Basic Information List

Table 92. Curia Description and Business Overview

Table 93. Curia Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 94. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Curia (2019-2024)

Table 95. Curia Recent Developments

Table 96. Sterling Pharma Solutions Basic Information List

Table 97. Sterling Pharma Solutions Description and Business Overview

Table 98. Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 99. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Sterling Pharma Solutions (2019-2024)

Table 100. Sterling Pharma Solutions Recent Developments

Table 101. Eurofins CDMO Basic Information List

Table 102. Eurofins CDMO Description and Business Overview

Table 103. Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Products, Services and Solutions

Table 104. Revenue (US$ Million) in Active Pharmaceutical Ingredients (API) CDMO Business of Eurofins CDMO (2019-2024)

Table 105. Eurofins CDMO Recent Developments

Table 106. Key Raw Materials Lists

Table 107. Raw Materials Key Suppliers Lists

Table 108. Active Pharmaceutical Ingredients (API) CDMO Downstream Customers

Table 109. Active Pharmaceutical Ingredients (API) CDMO Distributors List

Table 110. Research Programs/Design for This Report

Table 111. Key Data Information from Secondary Sources

Table 112. Key Data Information from Primary Sources

Table 113. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Active Pharmaceutical Ingredients (API) CDMO Product Picture

Figure 2. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value (2019-2030) & (US$ Million)

Figure 4. Active Pharmaceutical Ingredients (API) CDMO Report Years Considered

Figure 5. Global Active Pharmaceutical Ingredients (API) CDMO Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Active Pharmaceutical Ingredients (API) CDMO Revenue in 2023

Figure 7. Active Pharmaceutical Ingredients (API) CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Macromolecular API Picture

Figure 9. Small Molecule API Picture

Figure 10. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Clinical

Figure 13. Product Picture of Commercial

Figure 14. Product Picture of Others

Figure 15. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Active Pharmaceutical Ingredients (API) CDMO Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Active Pharmaceutical Ingredients (API) CDMO Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Active Pharmaceutical Ingredients (API) CDMO Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Active Pharmaceutical Ingredients (API) CDMO Sales Value (%), (2019-2030)

Figure 28. United States Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 34. China Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 36. China Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 46. India Active Pharmaceutical Ingredients (API) CDMO Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Active Pharmaceutical Ingredients (API) CDMO Sales Value by Type (%), 2023 VS 2030

Figure 48. India Active Pharmaceutical Ingredients (API) CDMO Sales Value by Application (%), 2023 VS 2030

Figure 49. Active Pharmaceutical Ingredients (API) CDMO Industrial Chain

Figure 50. Active Pharmaceutical Ingredients (API) CDMO Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Chrysalis Oil Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26N13078

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Eucommia Ulmoides Extract Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-3L13782

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global MRSA Drugs Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26S13718

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Ferrous Citrate Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-16S12875

Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions